PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT
Abstract
Among epileptic encephalopathies, the Lennox–Gastaut syndrome is considered to be one of the most severe. It is a childhood-onset disease that leads to early disability and mental retardation and is associated with significant costs of medical care and patient nursing. In the Russian Federation, the supposed number of patients with the Lennox–Gastaut syndrome is between 1400 and 9240 people. Rufinamide is one of the most powerful agents being used for the adjuvant therapy of this syndrome. In order to evaluate the efficacy of the drug in this pathology, a systematic review of publications of the results of the respective clinical studies was performed. Eleven articles were selected for generation of pooled groups and meta-analysis. Rufinamide used as an adjunctive therapy has been shown to substantially increase the chances of successful result (HR=3.1 [2.0; 4.9], p=0.000). Pharmacoeconomic modelling (a decision tree type) allowed revealing that the use of rufinamide adjunctive therapy for the Lennox–Gastaut syndrome reduces total costs of treatment and nursing of these patients with minimum effect on the budget.
About the Authors
N. K. Mazina
Kirov State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
doctor of medical sciences, professor, Head of the Department of pharmacology,
ul. K. Marksa, 112, g. Kirov, 610020
P. V. Mazin
Kirov State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
assistant at the Department of pharmacology,
ul. K. Marksa, 112, g. Kirov, 610020
Yu. V. Kislitsin
Kirov State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
doctor of medical sciences, professor, Head of the Department of neurology and neurosurgery,
ul. K. Marksa, 112, g. Kirov, 610020
E. M. Markova
Kirov State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
senior researcher at the Laboratory of pharmacological bioenergetics and membranology,
ul. K. Marksa, 112, g. Kirov, 610020
References
1. Voronina T.A. , Nerobkova L.N., Avakyan G.N., Khromykh E.A., Gaidukov I.O, Avakyan G.G. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2013; 4: 29-31.
2. Internet pharmacy, 2016. URL: http://www.amt.allergist.ru/sinonim/rufinamid. Accessed: 02.01.2016.
3. The magnitude of the effect Calculator, 2016 g. URL: http://www.campbellcollaboration.org/escalc/html/EffectSizeCalculator-ESTypes.php. Accessed: 04.01.2016.
4. Inflation Calculator, 2016. URL: http://www.statbureau.org/ru/russia/inflation-calculator. Accessed: 04.01.2016.
5. Karlov V.A. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 2: 71-79.
6. Mizinova M.A., Mil'chakova L.E., Lebedeva A.V., Kovaleva I.Yu., Pavlov I.A., Gekht A.B. Prilozhenie k Zhurnalu nevrologii i psikhiatrii im. S.S. Korsakova. 2011; 2 (5): 58-65.
7. Mironov M.B., Mukhin K.Yu., Krasil'shchikova T.M., Dolinina A.F., Petrukhin A.S. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2013; 3: 24-33.
8. Mikhailov V.A. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 39-44.
9. Mukhin K.Yu. Russkii zhurnal detskoi nevrologii. 2015; 10 (2): 19-31.
10. Mukhin K.Yu., Pylaeva O.A. Russkii zhurnal detskoi nevrologii. 2015; 10 (2): 32-37.
11. Semakina N.V., Mikhailov V.A., Bagaev V.I. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2013; 1: 31-37.
12. Kholin A.A., Zavadenko N.N., Il'ina E.S., Fedonyuk I.D., Kolpakchi L.M., Khalilov V.S., Kosyakova E.S. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2013; 3: 34-40.
13. Shagrova E.V., Orekhova N.V., Leonova M.V., Vlasov P.N. Russkii zhurnal detskoi nevrologii. 2012; 7 (3): 17-24.
14. Shal'kevich L.V., Smychek V.B., Kudlach A.I. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2015; 3: 26-31.
15. Shchederkina I.O., Zavadenko N.N., Koltunov I.E. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2013; 4: 49-53.
16. Beniczky S.A., Viken J., Jensen L.T., Andersen N.B. Bone mineral density in adult patients treated with various antiepileptic drugs. Seizure. 2012 Jul; 21 (6): 471-2.
17. Clements K., Skorinski M., O’Sillivan A.K. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome. Epilepsy & Behavior. 2013; 29: 184-189.
18. Coppola G., Grosso S., Franzoni E., Veggiotti P. et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Seizure. 2010; 19: 587-591.
19. Ferrie C., Patel A. Treatment of Lennox-Gastaut Syndrome (LGS). European journal of paediatric neurology. 2009; 13: 493-504.
20. Glauser T., Kluger G., Sachdeo R., Krauss G et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008; 70 (20): 1950-8.
21. Grosso S., Coppola G., Dontin S., Gobbi G. et al. Efficacy and safety of rufinamide in children under four years of age with drugresistant epilepsies. European journal of paediatric neurology. 2014; 18: 641-645.
22. Jae Yeon Kim, Cha Gon Lee, Hee Joon Yu, Sook Hyun Nam et al. The Efficacy and Tolerability of Rufinamide in Intractable Pediatric Epilepsy. Journal of Epilepsy Research. 2012; 2 (2): 33-37.
23. Joseph J., Schultz R., Wilfong A. Rufinamide for refractory epilepsy in a pediatric and young adult population. Epilepsy Research. 2011; 93: 87-89.
24. Kessler S.K., VcCarty A., Cnaau A., Dlugos D.J. Retention rates of rufinamide in pediatric epilepsy patients with and without LennoxGastaut Syndrome. Epilepsy Research. 2015; 112: 18-26.
25. Kluger G., Kurlemann G., Haberlandt E., Ernst J. et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experience. Epilepsy & Behavior. 2009; 14: 491-495.
26. Motte J., Trevathan E., Arvidsson J., Barrera M. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. The New England Journal of Medicine. 1997 Dec 18; 337 (25): 1807-12.
27. Ohtsuka Y., Yoshinaga H., Shirasaka Y., Takayama R. et al. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: A randomized double-blind placebo-controlled trial in Japan. Epilepsy Research. 2014; 108: 1627-1636.
28. Sachdeo R., Glauser T., Ritter F., Reife R. et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology. 10 June 1999; 52 (9): 1882-1887.
29. Se Hee Kim, Jeong Ho Lee, HyeWon Ryu, Byung Chan Lim et al. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalized epilepsy. Epileptic Disord. 2013; 15 (1): 49-54.
30. Skorinski M., Klements K.M., O’Sillivan A.K. Budget Impact Analysis of Antiepileptic Drugs for Lennox-Gastaut Syndrome. J. of Managed Care Pharmacy JMCP. 2014; 4 (20): 400-6.
31. Thome-Souza S., Kadish N., Ramgopal S., Fernandez I. et al. Safety and retention rate of rufinamide in 300 patients: A single pediatric epilepsy center experience. Epilepsia. 2014; 55 (8): 1235-1244.
32. van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatric Disease and Treatment. 2008; 4 (6): 1001-1019.
33. Vigevano F., Arzimanoglou A., Plouin P., Specchio N. Therapeutic approach to epileptic encephalopathies. Epilepsia. 2013; 54 (8): 45-50.
For citation:
Mazina N.K., Mazin P.V., Kislitsin Y.V., Markova E.M. PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2016;9(1):15-22. (In Russ.) https://doi.org/10.17749/2070-4909.2016.9.1.015-022
Views: 390
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 